

Dupilumab for treating moderate to severe atopic dermatitis

Information for the public

Published: 1 August 2018

www.nice.org.uk

Dupilumab (Dupixent), with topical corticosteroids, is available on the NHS for moderate to severe atopic dermatitis (eczema) in adults. It is a possible treatment only when the dermatitis has not improved with other treatments, for example, ciclosporin, methotrexate, azathioprine and mycophenolate, or these can't be taken.

Treatment with dupilumab should be stopped after 16 weeks if the dermatitis does not improve enough.

When assessing how dermatitis affects your quality of life, healthcare professionals should take into account any disabilities or difficulties in communicating you might have.

If you are not eligible for dupilumab but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more

These organisations can give you advice and support:

- [British Skin Foundation](#), 0207 391 6347
- [National Eczema Society](#), 0800 089 1122 (helpline to speak with a Dermatology Nurse Specialist; operates 8am–8pm Monday to Friday)

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3042-5